Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Intercalated chemotherapy and erlotinib for advanced NSCLC : high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
Avtorji:ID Zwitter, Matjaž (Avtor)
ID Stanič, Karmen (Avtor)
ID Rajer, Mirjana (Avtor)
ID Kern, Izidor (Avtor)
ID Vrankar, Martina (Avtor)
ID Edelbaher, Natalija (Avtor)
ID Kovač, Viljem (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (590,54 KB)
MD5: 4D15D54FD12A329B5D885D617B42F63C
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Background. Pharmaco-dynamic separation of cytotoxic and targeted drugs might avoid their mutual antagonistic effect in the treatment of advanced non-small cell lung cancer (NSCLC). Patients and methods. Eligible patients were treatment-naive with stage IIIB or IV NSCLC. In addition, inclusion was limited to never-smokers or light smokers or, after 2010, to patients with activating epidermal growth-factor receptor (EGFR) mutations. Treatment started with 3-weekly cycles of gemcitabine and cisplatin on days 1, 2 and 4 and erlotinib on days 5 to 15. After 4 to 6 cycles, patients continued with erlotinib maintenance. Results. Fifty-three patients were recruited into the trial: 24 prior to 2010 (of whom 9 were later found to be positive for EGFR mutations), and 29 EGFR mutation-positive patients recruited later. Unfavourable prognostic factors included stage IV disease (51 patients - 96%), performance status 2%3 (11 patients - 21%) and brain metastases (15 patients - 28%). Grade 4 toxicity included 2 cases of neutropenia and 4 thrombo-embolic events. The 15 EGFR negative patients had 33% objective response rate, median progression-free survival (PFS) 6.0 months and median survival 7.6 months. Among 38 EGFR positive patients, complete response (CR) or partial response (PR) were seen in 16 (42.1%) and 17 (44.7%) cases, respectively. PET-CT scanning was performed in 30 patients and confirmed CR and PR in 16 (53.3%) and 9 (30.0%) cases, respectively. Median PFS for EGFR mutated patients was 21.2 months and median survival was 32.5 months. Conclusions. While patients with EGFR negative tumors do not benefit from addition of erlotinib, the intercalated schedule appears most promising for those with EGFR activating mutations.
Ključne besede:non-small cell lung cancer, EGFR activating mutations, gemicitabine, erlotinib
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.12.2014
Založnik:Association of Radiology and Oncology
Leto izida:2014
Št. strani:str. 361-368, III
Številčenje:Vol. 48, no. 4
Izvor:Ljubljana
PID:20.500.12556/DiRROS-18669 Novo okno
UDK:616.2-006
ISSN pri članku:1318-2099
DOI:10.2478/raon-2014-0038 Novo okno
COBISS.SI-ID:1882747 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:11.04.2024
Število ogledov:717
Število prenosov:225
Metapodatki:XML DC-XML DC-RDF
:
ZWITTER, Matjaž, STANIČ, Karmen, RAJER, Mirjana, KERN, Izidor, VRANKAR, Martina, EDELBAHER, Natalija in KOVAČ, Viljem, 2014, Intercalated chemotherapy and erlotinib for advanced NSCLC : high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations. Radiology and oncology [na spletu]. 2014. Vol. 48, no. 4, p. 361–368, iii. [Dostopano 6 april 2025]. DOI 10.2478/raon-2014-0038. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=18669
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:nedrobnocelični rak, pljučni rak, gemicitabin, cisplatin


Nazaj